Laquinimod in the treatment of multiple sclerosis: a review of the data so far

References

• NylanderAHaflerDAMultiple sclerosisJ Clin Invest201212241180118822466660
   PubMed Web of Science ®Google Scholar
• HauserSLChanJROksenbergJRMultiple sclerosis: prospects and promiseAnn Neurol201374331732723955638
   PubMed Web of Science ®Google Scholar
• GrigoriadisNvan PeschVParadigMS GroupA basic overview of multiple sclerosis immunopathologyEur J Neurol201522Suppl 231326374508
   PubMedGoogle Scholar
• De StefanoNAirasLGrigoriadisNClinical relevance of brain volume measures in multiple sclerosisCNS Drugs201428214715624446248
   PubMed Web of Science ®Google Scholar
• KutzelniggALassmannHPathology of multiple sclerosis and related inflammatory demyelinating diseasesHandb Clin Neurol2014122155824507512
   PubMedGoogle Scholar
• Kolb-SobierajCGuptaSWeinstock-GuttmanBLaquinimod therapy in multiple sclerosis: a comprehensive reviewNeurol Ther201431293926000222
   PubMedGoogle Scholar
• ThöneJGoldRReview of laquinimod and its therapeutic potential in multiple sclerosisExpert Opin Pharmacother201314182545255224215556
   PubMed Web of Science ®Google Scholar
• NoseworthyJHWolinskyJSLublinFDLinomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide InvestigatorsNeurology20005491726173310802775
   PubMed Web of Science ®Google Scholar
• BrunmarkCRunstromAOhlssonLThe new orally active immuno regulator laquinimod (Abr-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJ Neuroimmunol200213016317212225898
   PubMed Web of Science ®Google Scholar
• ThöneJGoldRLaquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosisExpert Opin Drug Metab Toxicol20117336537021306281
   PubMed Web of Science ®Google Scholar
• BrückWWegnerCInsight into the mechanism of laquinimod actionJ Neurol Sci20113061–217317921429524
   PubMed Web of Science ®Google Scholar
• TuvessonHHallinIPerssonRSparreBGunnarssonPOSeidegårdJCytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulatorDrug Metab Dispos200533686687215764719
   PubMed Web of Science ®Google Scholar
• LinkerRALeeDHModels of autoimmune demyelination in the central nervous system: on the way to translational medicineExp Transl Stroke Med20091520142992
   PubMedGoogle Scholar
• RunströmALeandersonTOhlssonLAxelssonBInhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type miceJ Neuroimmunol20061731–2697816472873
   PubMed Web of Science ®Google Scholar
• ThöneJEllrichmannGSeubertSModulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factorAm J Pathol2012180126727422152994
   PubMed Web of Science ®Google Scholar
• WegnerCStadelmannCPförtnerRLaquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitisJ Neuroimmunol20102271–213314320684995
   PubMed Web of Science ®Google Scholar
• RostamiACiricBRole of Th17 cells in the pathogenesis of CNS inflammatory demyelinationJ Neurol Sci20133331–2768723578791
   PubMed Web of Science ®Google Scholar
• Schulze-TopphoffUShettyAVarrin-DoyerMLaquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunityPLoS One201273e3379722479444
   PubMed Web of Science ®Google Scholar
• MishraMKWangJSilvaCMackMYongVWKinetics of proinflam-matory monocytes in a model of multiple sclerosis and its perturbation by laquinimodAm J Pathol2012181264265122749771
   PubMed Web of Science ®Google Scholar
• MishraMKWangJKeoughMBLaquinimod reduces neuroax-onal injury through inhibiting microglial activationAnn Clin Transl Neurol20141640942225356411
   PubMed Web of Science ®Google Scholar
• JolivelVLuessiFMasriJModulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosisBrain2013136Pt 41048106623518712
   PubMed Web of Science ®Google Scholar
• GurevichMGritzmanTOrbachRTullerTFeldmanAAchironALaquinimod suppresses antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression studyJ Neuroimmunol20102211–2879420347159
   PubMed Web of Science ®Google Scholar
• StasiolekMLinkerRAHayardenyLBar IlanOGoldRImmune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled studyImmun Inflamm Dis201532455526029365
   PubMedGoogle Scholar
• LundBTKellandEEHayardenyLBarilanOGilmoreWWeinerLPAssessment of changes in immune measures of multiple sclerosis patients treated with laquinimodJ Neuroimmunol20132631–210811523920036
   PubMed Web of Science ®Google Scholar
• KellandEEGilmoreWHayardenyLWeinerLPLundBTIn vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cellsJ Neurol Sci20143461–2667425125045
   PubMed Web of Science ®Google Scholar
• AharoniRSaadaREilamRHayardenyLSelaMArnonROral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitisJ Neuroimmunol20122511–2142422749337
   PubMed Web of Science ®Google Scholar
• BrückWPförtnerRPhamTReduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelinationActa Neuropathol201212434114–2422766690
   PubMed Web of Science ®Google Scholar
• RuffiniFRossiSBergamaschiALaquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitisMult Scler20131981084109423232603
   PubMed Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• ComiGAbramskyOArbizuTOral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled studyMult Scler201016111360136620834039
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLALLEGRO Study GroupPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med2012366111000100922417253
   PubMed Web of Science ®Google Scholar
• VollmerTLSorensenPSSelmajKBRAVO Study GroupA randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosisJ Neurol2014261477378324535134
   PubMed Web of Science ®Google Scholar
• FilippiMRoccaMAPaganiEPlacebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageJ Neurol Neurosurg Psychiatry201485885185824029546
   PubMed Web of Science ®Google Scholar
• BjorkAJonssonAFexTHedlundGinventorsActive Biotech Ab. assigneeQuinoline derivativesUnited States Patent US 6593343 B22003715
   Google Scholar
• European Medicine AgencyRefusal of the marketing authorisation for Nerventra (laquinimod)European Medicine Agency2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdfAccessed February 18, 2016
   Google Scholar